Oncternal Therapeutics to Participate in the BTIG Virtual Biotechnology Conference
SAN DIEGO, Aug. 02, 2021 (GLOBE NEWSWIRE) -- Oncternal Therapeutics (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that management will participate in the BTIG Virtual Biotechnology Conference being held August 9-10, 2021.
BTIG Virtual Biotechnology Conference – August 9-10, 2021
James Breitmeyer, President and Chief Executive Officer will present a corporate overview on Monday, August 9th at 12:00pm (ET), and the company will be available for one-on-one meetings.
Live Link:
To listen to the live event, please contact your BTIG representative.
About Oncternal Therapeutics:
Oncternal Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies for the treatment of cancers with critical unmet medical need. Oncternal focuses drug development on promising yet untapped biological pathways implicated in cancer generation or progression. The clinical pipeline includes , an investigational monoclonal antibody designed to inhibit the ROR1 pathway, a type I tyrosine kinase-like orphan receptor, that is being evaluated in a Phase 1/2 clinical trial in combination with ibrutinib for the treatment of patients with mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL) and in an investigator-sponsored, Phase 1b clinical trial in combination with paclitaxel for the treatment of women with HER2-negative metastatic or locally advanced, unresectable breast cancer, as well as a Phase 2 clinical trial of cirmtuzumab in combination with venetoclax, a Bcl-2 inhibitor, in patients with relapsed/refractory CLL. Oncternal is also developing a chimeric antigen receptor T cell () therapy that targets ROR1, which is currently in preclinical development as a potential treatment for hematologic cancers and solid tumors. The clinical pipeline also includes , an investigational targeted small-molecule inhibitor of the ETS family of oncoproteins, that is being evaluated in a Phase 1/2 clinical trial for patients with Ewing sarcoma alone and in combination with vincristine chemotherapy. More information is available at .
Oncternal Contacts:
Company Contact
Richard Vincent
858-434-1113
Investor Contact
Corey Davis, Ph.D.
LifeSci Advisors
212-915-2577
